孕激素
子宫内膜癌
医学
子宫内膜增生
生育率
非典型增生
妇科
肿瘤科
癌
癌症
癌症研究
内科学
雌激素
人口
环境卫生
作者
Mu Lv,Peiqin Chen,Mingzhu Bai,Yan Huang,Linxia Li,Feng Yan,Hong Liao,Wenxin Zheng,Xiaojun Chen,Zhenbo Zhang
出处
期刊:Cancers
[MDPI AG]
日期:2022-12-15
卷期号:14 (24): 6210-6210
被引量:2
标识
DOI:10.3390/cancers14246210
摘要
With a younger tendency in morbidity age, endometrial cancer (EC) incidence has grown year after year. Worse, even more commonly occurring is endometrial hyperplasia (EH), which is a precancerous endometrial proliferation. For young women with early EC and EH who want to preserve fertility, progestin therapy has been utilized as a routine fertility-preserving treatment approach. Nevertheless, progestin medication failure in some patients is mostly due to progestin resistance and side effects. In order to further analyze the potential mechanisms of progestin resistance in EH and EC, to provide theoretical support for effective therapeutic strategies, and to lay the groundwork for searching novel treatment approaches, this article reviews the current therapeutic effects of progestin in EH and EC, as well as the mechanisms and molecular biomarkers of progestin resistance, and systematically expounds on the potential therapeutic methods to overcome progestin resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI